Media Relations News Releases Year: - Any -201820172016 Items per page 102550 Oct 18, 2018 Summary ToggleNovartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth Oct 4, 2018 Summary ToggleSandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges Sep 21, 2018 Summary ToggleNovartis announces positive CHMP opinion for one-time gene therapy Luxturna™ to treat children and adults with rare inherited retinal disease Sep 17, 2018 Summary ToggleWorld’s largest Alzheimer’s survey reveals most adults believe a cure will be developed in their lifetime Sep 12, 2018 Summary ToggleNovartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS Aug 27, 2018 Summary ToggleNovartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) Aug 25, 2018 Summary ToggleNovartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode Jul 30, 2018 Summary ToggleNovartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention Jul 18, 2018 Summary ToggleNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Jun 29, 2018 Summary ToggleNovartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
